P
Paul M. Ness
Researcher at Johns Hopkins University
Publications - 362
Citations - 15229
Paul M. Ness is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Blood transfusion & Platelet transfusion. The author has an hindex of 61, co-authored 356 publications receiving 13747 citations. Previous affiliations of Paul M. Ness include Brigham and Women's Hospital & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.
TL;DR: Effective treatment with 91 percent survival is available for patients with TTP-HUS, and treatment with aspirin and dipyridamole was effective in those with a poor response to plasma exchange.
Journal ArticleDOI
The Declining Risk of Post-Transfusion Hepatitis C Virus Infection
James G. Donahue,Alvaro Muñoz,Paul M. Ness,Donald E. Brown,David H. Yawn,Hugh A. McAllister,Bruce A. Reitz,Kenrad E. Nelson +7 more
TL;DR: The incidence of post-transfusion hepatitis C has decreased markedly since the implementation of donor screening for surrogate markers and antibodies to HCV and the trend toward decreasing risk with increasingly stringent screening of donors was statistically significant.
Journal ArticleDOI
Dose of prophylactic platelet transfusions and prevention of hemorrhage.
Sherrill J. Slichter,Richard M. Kaufman,Susan F. Assmann,Jeffrey McCullough,Darrell J. Triulzi,Ronald G. Strauss,Terry Gernsheimer,Paul M. Ness,Mark E. Brecher,Cassandra D. Josephson,Barbara A. Konkle,Robert D. Woodson,Thomas L. Ortel,Christopher D. Hillyer,Donna Skerrett,Keith R. McCrae,Steven R. Sloan,Lynne Uhl,James N. George,Victor M. Aquino,Catherine S. Manno,Janice G. McFarland,John R. Hess,Cindy A. Leissinger,Suzanne Granger +24 more
TL;DR: Low doses of platelets administered as a prophylactic transfusion led to a decreased number of platelet transfused per patient but an increased number of transfusions given.
Journal ArticleDOI
Effects of Red-Cell Storage Duration on Patients Undergoing Cardiac Surgery
Marie E. Steiner,Paul M. Ness,Susan F. Assmann,Darrell J. Triulzi,Steven R. Sloan,Meghan Delaney,Suzanne Granger,Elliott Bennett-Guerrero,Morris A. Blajchman,Vincent A. Scavo,Jeffrey L. Carson,Jerrold H. Levy,Glenn J.R. Whitman,Pamela D'Andrea,Shelley Pulkrabek,Thomas L. Ortel,Larissa Bornikova,Thomas J. Raife,Kathleen E. Puca,Richard M. Kaufman,Gregory A. Nuttall,Pampee P. Young,Samuel Youssef,Richard M. Engelman,Philip E. Greilich,Ronald Miles,Cassandra D. Josephson,Arthur W. Bracey,Rhonda Cooke,Jeffrey McCullough,Robert Hunsaker,Lynne Uhl,Janice G. McFarland,Yara A. Park,Melissa M. Cushing,Charles T. Klodell,Ravindra Karanam,Pamela R. Roberts,Cornelius M. Dyke,Eldad A. Hod,Christopher P. Stowell +40 more
TL;DR: The duration of red-cell storage was not associated with significant differences in the change in Multiple Organ Dysfunction Score and the transfusion of red cells stored for 21 days or more among patients 12 years of age or older who were undergoing complex cardiac surgery was not found to be superior.
Journal ArticleDOI
Fibrin glue: the perfect operative sealant?
Joan Gibble,Paul M. Ness +1 more
TL;DR: Fibrin glue (fibrin sealant) has been advocated by many surgeons as the material that best approaches the ideal operative sealant, and it appears to have no tissue toxicity, promotes a firm seal in seconds to minutes, is reabsorbed in days to weeks following application, and appears to promote local tissue growth.